Comparative Pharmacology
Head-to-head clinical analysis: SEMPREX D versus TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEMPREX D versus TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES.
SEMPREX-D vs TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
1 capsule (triprolidine 2.5 mg/pseudoephedrine 60 mg) orally every 4-6 hours; not to exceed 4 doses in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Triprolidine: 5-7 hours. Pseudoephedrine: 4-8 hours (pH-dependent; alkaline urine prolongs half-life). Clinical context: Dose adjustment needed in renal impairment for pseudoephedrine.
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Triprolidine: Renal excretion of metabolites (approx. 60%) and unchanged drug (less than 5%). Pseudoephedrine: Primarily renal elimination as unchanged drug (70-90%), with minor hepatic metabolism. Fecal excretion is negligible for both.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine